US CDC Panel Supports Moderna, Janssen COVID Vaccine Boosters But Strips Out Preference Language For Homologous Dosing
ACIP pushes back on proposed policy recommendation that the same product used for the primary regimen should be used for the booster, saying risk/benefit and other considerations necessitate more flexibility afforded by 'mix and match' approach.
You may also be interested in...
Moderna’s COVID-19 Vaccine Packaging Poses Booster Tracking, Safety Surveillance Challenges, Experts Say
Since company is using same vial and NDC code for primary series and booster dose, which is half the amount, immunization registries will not be able to capture how much Moderna vaccine an individual actually gets for their third dose.
After US FDA authorization for additional COVID vaccine shots, the focus now shifts to CDC’s advisory committee, which may be concerned about variations in eligible populations, timing and dosing when it comes to giving a booster different from the primary vaccination series.
‘If I had been in the room, I would have voted yes,’ CDC director says of ACIP. ‘This was a scientific close call. ... And that was how my recommendations came out after listening to all of their scientific deliberations.’